Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Similar Items

• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  od: Nair, Bijay, i dr.
  Izdano: (2010)
• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  od: Waheed, Sarah, i dr.
  Izdano: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  od: Hoering, Antje, i dr.
  Izdano: (2009)
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  od: van Rhee, Frits, i dr.
  Izdano: (2010)
• Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
  od: Heuck, Christoph J, i dr.
  Izdano: (2012)